Patrick Humphrey

University of Cambridge, Cambridge, England, United Kingdom 
"Patrick Humphrey"
Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Page C, Humphrey P. (2013) Sir David Jack: an extraordinary drug discoverer and developer. British Journal of Clinical Pharmacology. 75: 1213-8
Long DD, Armstrong SR, Beattie DT, et al. (2012) Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation. Bioorganic & Medicinal Chemistry Letters. 22: 6048-52
Long DD, Armstrong SR, Beattie DT, et al. (2012) Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749. Bioorganic & Medicinal Chemistry Letters. 22: 4849-53
Hill CM, Krause KM, Lewis SR, et al. (2010) Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin. Antimicrobial Agents and Chemotherapy. 54: 2814-8
McKinnell RM, Armstrong SR, Beattie DT, et al. (2009) A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. Journal of Medicinal Chemistry. 52: 5330-43
Lunde CS, Hartouni SR, Janc JW, et al. (2009) Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrobial Agents and Chemotherapy. 53: 3375-83
Humphrey PP. (2008) The discovery and development of the triptans, a major therapeutic breakthrough. Headache. 48: 685-7
Humphrey PP. (2007) The discovery of a new drug class for the acute treatment of migraine. Headache. 47: S10-9
Michel AD, Xing M, Thompson KM, et al. (2006) Decavanadate, a P2X receptor antagonist, and its use to study ligand interactions with P2X7 receptors. European Journal of Pharmacology. 534: 19-29
Higgins DL, Chang R, Debabov DV, et al. (2005) Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. 49: 1127-34
See more...